Non-small-cell lung cancer is the most prevalent type of lung cancer in the world and the leading cause of cancer death, accounting for 1.4 million deaths annually.1 Non-small-cell lung cancer consists of several histological subtypes, the two most common being adenocarcinoma (AC) and squamous cell carcinoma (SCC).2 While targeted therapies, such as those that target epidermal growth factor receptor (EGFR), have been successful in improving response rates in patients with AC tumors, the majority of SCC tumors lack specific targetable mutations. This evidence concerns the gene EGFR and adenocarcinoma.